Lexicon Pharmaceuticals (LXRX) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Strategic focus and pipeline overview

• Refocused efforts on cardiometabolic diseases, with lead programs in HCM, type 1 diabetes, and diabetic neuropathic pain, plus an obesity partnership with Novo Nordisk.

• Emphasizing unique dual SGLT1/2 inhibition for differentiation and targeting indications with high unmet need and potential for first-in-class status.

• Commercial strategy aims for freedom of operation and value creation by targeting areas with limited competition.

HCM program and clinical development

• SONATA-HCM phase III trial completed enrollment, with data expected in Q1 next year; pragmatic design allows broad inclusion and real-world relevance.

• Sotagliflozin shows consistent benefit across ejection fractions, potentially modifying disease in both obstructive and non-obstructive HCM.

• Primary endpoint is KCCQ score, with secondary endpoints including NYHA class and exploratory measures; FDA alignment achieved.

• Over-enrollment and lower efficacy bar from recent studies increase confidence in meeting market expectations.

• Commercial preparations underway, including market research and team expansion, to support potential launch.

Competitive landscape and positioning

• Strategy focuses on indications where sotagliflozin can be first and only, avoiding crowded markets and enabling complementary use with other agents.

• SONATA-HCM will provide unique data on combination therapy with CMIs, potentially informing future treatment paradigms.